Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors

Transplantation Proceedings

Volumn 37, Issue 4 SUPPL., 2005, Pages 4-17

  Eisen, H ^a,f   Kobashigawa, J ^b   Starling, R C ^c   Valantine, H ^d   Mancini, D ^e  

^a DREXEL UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PURINE SYNTHESIS INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BACTERIAL PNEUMONIA; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CORONARY ARTERY; CYTOMEGALIC INCLUSION BODY DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FOLLOW UP; GINGIVA HYPERTROPHY; GRAFT DYSFUNCTION; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTRAVASCULAR ULTRASOUND; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; METABOLIC DISORDER; MORTALITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUNICA MEDIA;

EID: 16244406560     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.02.118     Document Type: Article

References (48)

1. Organ Procurement and Transplantation Network reports 1996-2001. Available at: www.optn.org. Accessed February 2005
2. J. Kobashigawa Review what is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med 1 2000 166
3. J. Jimenez, S.R. Kapadia, M.H. Yamani Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study J Heart Lung Transplant 20 2001 393
4. D.O. Taylor, L.B. Edwards, P.J. Mohacsi The registry of the international society for heart and lung transplantation: twentieth official adult heart transplant report--2003 J Heart Lung Transplant 222 2003 616
5. S.R. Kapadia, K.M. Ziada, P.L. L'Allier Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging J Heart Lung Transplant 19 2000 167
6. M.E. Billingham Histopathology of graft coronary disease J Heart Lung Transplant 11 suppl 1992 S38
7. J.K. Kirklin, J.B. Young, D.C. McGiffin Cardiac allograft vasculopathy (chronic rejection) J.K. Kirklin J.B. Young D.C. McGiffin Heart Transplantation 2002 Churchill Livingstone New York p 615
8. F. Moien-Ashfari, B.M. McManus, I. Laher Immunosuppression and transplant vascular disease: benefits and adverse effects Pharmacol Ther 100 2003 141
9. S.P. Pinney, D. Mancini Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention and treatment Curr Opin Cardiol 19 2004 170
10. A.L.P. Caforio, F. Tona, A. Belloni Fortina Immune and non-immune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression Am J Transplant 4 2004 962
11. H.A. Valantine Cardiac allograft vasculopathy after heart transplantation: risk factors and management J Heart Lung Transplant 23 2004 S187
12. J.K. Kirklin, D.C. Naftel, J. Parker Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study J Thorac Cardiovasc Surg 125 2003 881
13. M.T. Grattan, C.E. Moreno-Cabral, V.A. Starnes, P.E. Oyer, E.B. Stinson, N.E. Shumway Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis JAMA 261 1989 3561
14. A. Guedes, J.C. Tardif Intravascular ultrasound assessment of atherosclerosis Current Atherosclerosis Reports 6 2004 219
15. S.R. Kapadia, S.E. Nissen, K.M. Ziada Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis comparison by serial intravascular ultrasound imaging Circulation 98 1998 2672
16. D.H. Liang, S.Z. Gao, J. Botas Prediction of angiographic disease by intracoronary ultrasonographic findings in heart transplant recipients J Heart Lung Transplant 15 1996 980
17. G.S. Mintz, S.E. Nissen, W.D. Anderson American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS) J Am Coll Cardiol 37 2001 1478
18. P.R. Rickenbacker, F.J. Pinto, N.P. Lewis Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation Circulation 92 1995 3445
19. R. Mehra, H.O. Ventura, D.D. Stapleton, F.W. Smart, T.C. Collins, S.R. Ramee Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy J Heart Lung Transplant 14 1995 632
20. J. Kobashigawa First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation J Heart Lung Transplant 22 2003 711
21. J. Kobashigawa Multi-center intravascular ultrasound validation study among heart transplant recipients: outcomes after 5 years Am J Transplant 4 suppl 8 2004 549
22. J. Kobashigawa, L. Miller, D. Renlund A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients Transplantation 66 1998 507
23. K. Pethig, B. Heublein, T. Wahlers, O. Dannenberg, P. Oppelt, A. Haverich Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia J Heart Lung Transplant 23 2004 61
24. Kobashigawa J: Further analysis of the intravascular ultrasound (IVUS) data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients. Data presented at the 24th Annual Meeting of the ISHLT, San Francisco, Calif, USA, April 2004
25. Y. Matsumoto, A. Hof, Y. Baumlin, M. Muller, R.P. Hof Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid artery allografts in apolipoprotein E-deficient mice Transplantation 76 2003 1166
26. O.J. Cole, M. Shehata, K.M. Rigg Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model Transplant Proc 30 1998 2200
27. H.J. Schuurman, C. Pally, G. Weckbecker, W. Schuler, C. Bruns SDZ RAD inhibits cold ischemia-induced vascular remodeling Transplant Proc 31 1999 1024
28. C. Dambrin, J. Klupp, T. Birsan Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts Circulation 107 2003 2369
29. D. Mancini, S. Pinney, D. Burkhoff Use of rapamycin slows progression of cardiac transplantation vasculopathy Circulation 108 2003 48
30. A. Keogh, M. Richardson, P. Ruygrok Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary heart disease at 2 years A randomized clinical trial Circulation 110 2004 2694
31. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients N Engl J Med 349 2003 847
32. Kobashigawa J, Starling RC, Mehra MR, Bhat G, Kormos RL, Barr ML: Impact of ongoing post cardiac transplant risk factors on outcomes: a multi-center study Am J Transplant 3 suppl 2003 457
33. D. Mancini, M. Viganò, L.A., et al Pulpon: 24-month results of a multicenter study of Certican for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients Am J Transplant 3 suppl 5 2003 550
34. S. Sharma, B. Bhambi, W. Nyitray Sirolimus eluting coronary stents N Engl J Med 347 2002 1285
35. J.W. Moses, M.B. Leon, J.J. Popma Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315
36. E. Grube, S. Sonoda, F. Ikeno Six and twelve month results from first human experience using everolimus eluting stents with bio-absorbable polymer Circulation 109 2004 2168
37. Weill D: Role of cytomegalovirus in cardiac allograft vasculopathy Transpl Infect Dis 3 suppl 2 2001 44
38. M. Toyoda, K. Galfayan, O.A. Galera, A. Petrosian, L.S. Czer, S.C. Jordan Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients Transplant Immunology 5 1997 104
39. H.A. Valantine The role of viruses in cardiac allograft vasculopathy Am J Transplant 4 2003 169
40. R. Dorent, H. Valantine, J. Parameshwar Everolimus is associated with a reduced incidence of CMV infection in heart transplantation J Heart Lung Transplant 22 2003 S141
41. Keogh A: Calcineurin inhibitors in heart transplantation J Heart Lung Transplant 23 suppl 5s 2004 S202
42. H.J. Schuurman, S. Cottens, S. Fuchs SDZ, a new rapamycin derivative: synergism with cyclosporine Transplantation 64 1997 32
43. MacDonald A, Scarola J, Burke JT, Zimmerman JJ: Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus Clin Ther 22 suppl B 2000 B101
44. R.C. Starling, J.M. Hare, P. Hauptman Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling Am J Transplant 4 2004 2126
45. Lorber M, Ponticelli C, Whelchel J, et al: Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 19:145, 2005
46. S. Vitko, H. Tedesco, J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626
47. Magee J, Tedesco H, Pascual J, et al: Efficacy and safety of 2 doses of everolimus combined with reduced-dose Neoral in de novo kidney transplant recipients: 12 month analysis. Abstract presented at the American Transplant Congress May 14-19, Boston, Mass, USA
48. Lehmkuhl H, Hummel M, Dandel M, Grauhan C, Knossalla C, Hetzer R: Everolimus (Certican) in heart transplantation - early experience. Abstract accepted for presentation at ISHLT congress, Philadelphia, Pa, USA, April 5-9, 2005